Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;78(5):1190-1196.
doi: 10.1002/jpn3.12156. Epub 2024 Mar 26.

Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature

Collaborators
Free article

Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature

European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) et al. J Pediatr Gastroenterol Nutr. 2024 May.
Free article

Abstract

Nonalcoholic fatty liver disease (NAFLD) has been a commonly used term and diagnosis in paediatric hepatology, gastroenterology, and endocrinology clinics for over 30 years. A multisociety Delphi process has determined a new name "Steatotic Liver Disease" (SLD) as the overarching term for disorders associated with hepatic lipid accumulation. Our Societies give our support to steatotic liver disease as the best overarching term for use in our communities. Metabolic dysfunction-associated steatotic liver disease (MASLD) overcomes many of the shortcomings of the name NAFLD. Here, we highlight several points of the new nomenclature that are of particular importance for our community and their consequences for implementation including: diagnostic criteria, considering alternate diagnoses, practical implementation, research, advocacy, and education for paediatricians. As with all nomenclature changes, it will take a concerted effort from our paediatric societies to help integrate the optimal use of this into practice.

Keywords: diagnostic algorithm; fatty liver disease; metabolism.

PubMed Disclaimer

References

REFERENCES

    1. Lazarus JV, Kakalou C, Palayew A, et al. A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and obesity. Liver Int. 2021;41:2295‐2307.
    1. Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)‐associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6:864‐873.
    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multi‐society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542‐1556. doi:10.1016/j.jhep.2023.06.003
    1. Schwimmer JB, Newton KP, Awai HI, et al. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non‐alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38:1267‐1277.
    1. Eckel RH, Alberti KGMM, Grundy SM, et al. The metabolic syndrome. Lancet. 2010;375:181‐183.

Grants and funding